{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:43:56Z","timestamp":1792557836389,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11060-025-05128-4","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T18:15:28Z","timestamp":1752776128000},"page":"267-277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeting ataxia-telangiectasia mutated and cystine\/glutamate antiporter enhances radiotherapy efficacy and tumor suppression in glioblastoma"],"prefix":"10.1007","volume":"175","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1614-5429","authenticated-orcid":false,"given":"Mi Youn","family":"Seol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4083-6414","authenticated-orcid":false,"given":"Seo Hee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2106-6856","authenticated-orcid":false,"given":"Hong In","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"issue":"10","key":"5128_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N Engl J Med 352(10):987\u2013996","journal-title":"N Engl J Med"},{"issue":"8","key":"5128_CR2","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699\u2013708","journal-title":"N Engl J Med"},{"issue":"32","key":"5128_CR3","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","volume":"31","author":"MR Gilbert","year":"2013","unstructured":"Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA et al (2013) Dose-dense Temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 31(32):4085\u20134091","journal-title":"J Clin Oncol"},{"issue":"8","key":"5128_CR4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709\u2013722","journal-title":"N Engl J Med"},{"issue":"23","key":"5128_CR5","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1001\/jama.2015.16669","volume":"314","author":"R Stupp","year":"2015","unstructured":"Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA et al (2015) Maintenance therapy with Tumor-Treating fields plus Temozolomide vs Temozolomide alone for glioblastoma: A randomized clinical trial. JAMA 314(23):2535\u20132543","journal-title":"JAMA"},{"issue":"4","key":"5128_CR6","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.ejca.2014.12.019","volume":"51","author":"M Westphal","year":"2015","unstructured":"Westphal M, Heese O, Steinbach JP, Schnell O, Schackert G, Mehdorn M et al (2015) A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur J Cancer 51(4):522\u2013532","journal-title":"Eur J Cancer"},{"issue":"10","key":"5128_CR7","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","volume":"15","author":"R Stupp","year":"2014","unstructured":"Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK et al (2014) Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071\u2013\u200922072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15(10):1100\u20131108","journal-title":"Lancet Oncol"},{"key":"5128_CR8","first-page":"1079","volume":"6","author":"C Scaringi","year":"2013","unstructured":"Scaringi C, Enrici RM, Minniti G (2013) Combining molecular targeted agents with radiation therapy for malignant gliomas. Onco Targets Ther 6:1079\u20131095","journal-title":"Onco Targets Ther"},{"issue":"2","key":"5128_CR9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.radonc.2018.09.014","volume":"129","author":"JC Lin","year":"2018","unstructured":"Lin JC, Tsai JT, Chao TY, Ma HI, Chien CS, Liu WH (2018) MSI1 associates glioblastoma radioresistance via homologous recombination repair, tumor invasion and cancer stem-like cell properties. Radiother Oncol 129(2):352\u2013363","journal-title":"Radiother Oncol"},{"issue":"1","key":"5128_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13046-018-0758-7","volume":"37","author":"L Tang","year":"2018","unstructured":"Tang L, Wei F, Wu Y, He Y, Shi L, Xiong F et al (2018) Role of metabolism in cancer cell radioresistance and radiosensitization methods. J Exp Clin Cancer Res 37(1):87","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"5128_CR11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S0360-3016(01)01489-4","volume":"50","author":"S Tribius","year":"2001","unstructured":"Tribius S, Pidel A, Casper D (2001) ATM protein expression correlates with radioresistance in primary glioblastoma cells in culture. Int J Radiat Oncol Biol Phys 50(2):511\u2013523","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"5128_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3109\/09553002.2014.892227","volume":"90","author":"K Rycaj","year":"2014","unstructured":"Rycaj K, Tang DG (2014) Cancer stem cells and radioresistance. Int J Radiat Biol 90(8):615\u2013621","journal-title":"Int J Radiat Biol"},{"key":"5128_CR13","doi-asserted-by":"publisher","first-page":"102961","DOI":"10.1016\/j.critrevonc.2020.102961","volume":"150","author":"S Zhou","year":"2020","unstructured":"Zhou S, Zhang M, Zhou C, Wang W, Yang H, Ye W (2020) The role of epithelial-mesenchymal transition in regulating radioresistance. Crit Rev Oncol Hematol 150:102961","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"5128_CR14","first-page":"47","volume":"42","author":"CC Bridges","year":"2001","unstructured":"Bridges CC, Kekuda R, Wang H, Prasad PD, Mehta P, Huang W et al (2001) Structure, function, and regulation of human cystine\/glutamate transporter in retinal pigment epithelial cells. Investig Ophthalmol Vis Sci 42(1):47\u201354","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"5128_CR15","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1007\/s00432-011-1050-9","volume":"137","author":"L Xie","year":"2011","unstructured":"Xie L, Song X, Yu J, Guo W, Wei L, Liu Y et al (2011) Solute carrier protein family May involve in radiation-induced radioresistance of non-small cell lung cancer. J Cancer Res Clin Oncol 137:1739\u20131747","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"5128_CR16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.aanat.2010.07.003","volume":"192","author":"NE Savaskan","year":"2010","unstructured":"Savaskan NE, Ey\u00fcpoglu IY (2010) xCT modulation in gliomas: relevance to energy metabolism and tumor microenvironment normalization. Annals Anatomy-Anatomischer Anzeiger 192(5):309\u2013313","journal-title":"Annals Anatomy-Anatomischer Anzeiger"},{"key":"5128_CR17","doi-asserted-by":"publisher","first-page":"858462","DOI":"10.3389\/fonc.2022.858462","volume":"12","author":"N Jyotsana","year":"2022","unstructured":"Jyotsana N, Ta KT, DelGiorno KE (2022) The role of cystine\/glutamate antiporter SLC7A11\/xCT in the pathophysiology of cancer. Front Oncol 12:858462","journal-title":"Front Oncol"},{"issue":"1","key":"5128_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1227\/NEU.0b013e318276b2de","volume":"72","author":"S Takeuchi","year":"2013","unstructured":"Takeuchi S, Wada K, Toyooka T, Shinomiya N, Shimazaki H, Nakanishi K et al (2013) Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas. Neurosurgery 72(1):33\u201341","journal-title":"Neurosurgery"},{"issue":"10","key":"5128_CR19","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/sj.leu.2402238","volume":"15","author":"P Gout","year":"2001","unstructured":"Gout P, Buckley A, Simms C, Bruchovsky N (2001) Sulfasalazine, a potent suppressor of lymphoma growth by Inhibition of the xc\u2013\u2009cystine transporter: a new action for an old drug. Leukemia 15(10):1633\u20131640","journal-title":"Leukemia"},{"issue":"3","key":"5128_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2011.01.038","volume":"19","author":"T Ishimoto","year":"2011","unstructured":"Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H et al (2011) CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc\u2013\u2009and thereby promotes tumor growth. Cancer Cell 19(3):387\u2013400","journal-title":"Cancer Cell"},{"issue":"49","key":"5128_CR21","doi-asserted-by":"publisher","first-page":"5951","DOI":"10.1038\/onc.2015.60","volume":"34","author":"L Sleire","year":"2015","unstructured":"Sleire L, Skeie B, Netland I, F\u00f8rde H, Dodoo E, Selheim F et al (2015) Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc\u2013, leading to glutathione depletion. Oncogene 34(49):5951\u20135959","journal-title":"Oncogene"},{"key":"5128_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.critrevonc.2018.06.005","volume":"129","author":"J Kobiela","year":"2018","unstructured":"Kobiela J, Spychalski P, Marvaso G, Ciardo D, Dell\u2019Acqua V, Kraja F et al (2018) Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: systematic review. Crit Rev Oncol\/Hematol 129:91\u2013101","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"11","key":"5128_CR23","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.febslet.2011.05.013","volume":"585","author":"A Bensimon","year":"2011","unstructured":"Bensimon A, Aebersold R, Shiloh Y (2011) Beyond ATM: the protein kinase landscape of the DNA damage response. FEBS Lett 585(11):1625\u20131639","journal-title":"FEBS Lett"},{"key":"5128_CR24","doi-asserted-by":"crossref","unstructured":"Shiaw-Yih L, LIANG Y, Kaiyi L (2010) Multiple roles of BRIT1\/MCPH1 in DNA damage response, DNA repair, and Cancer suppression. Yonsei Med J.:295\u2013301","DOI":"10.3349\/ymj.2010.51.3.295"},{"issue":"10","key":"5128_CR25","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrm2514","volume":"9","author":"MF Lavin","year":"2008","unstructured":"Lavin MF (2008) Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 9(10):759\u2013769","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"5128_CR26","doi-asserted-by":"publisher","first-page":"eaat1719","DOI":"10.1126\/sciadv.aat1719","volume":"4","author":"ST Durant","year":"2018","unstructured":"Durant ST, Zheng L, Wang Y, Chen K, Zhang L, Zhang T et al (2018) The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci Adv 4(6):eaat1719","journal-title":"Sci Adv"},{"issue":"3","key":"5128_CR27","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/emboj.2010.330","volume":"30","author":"C Cosentino","year":"2011","unstructured":"Cosentino C, Grieco D, Costanzo V (2011) ATM activates the Pentose phosphate pathway promoting anti-oxidant defence and DNA repair. EMBO J 30(3):546\u2013555","journal-title":"EMBO J"},{"issue":"9","key":"5128_CR28","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1172\/JCI31604","volume":"117","author":"JS Eaton","year":"2007","unstructured":"Eaton JS, Lin ZP, Sartorelli AC, Bonawitz ND, Shadel GS (2007) Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis. J Clin Investig 117(9):2723\u20132734","journal-title":"J Clin Investig"},{"key":"5128_CR29","doi-asserted-by":"crossref","unstructured":"Chang L, Zhou B, Hu S, Guo R, Liu X, Jones SN et al (2008) ATM-mediated serine 72 phosphorylation stabilizes ribonucleotide reductase small subunit p53R2 protein against MDM2 to DNA damage. Proceedings of the National Academy of Sciences.;105(47):18519-24","DOI":"10.1073\/pnas.0803313105"},{"issue":"6003","key":"5128_CR30","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1126\/science.1192912","volume":"330","author":"Z Guo","year":"2010","unstructured":"Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT (2010) ATM activation by oxidative stress. Science 330(6003):517\u2013521","journal-title":"Science"},{"issue":"12","key":"5128_CR31","doi-asserted-by":"publisher","first-page":"7834","DOI":"10.1074\/jbc.M512894200","volume":"281","author":"P H\u00e5kansson","year":"2006","unstructured":"H\u00e5kansson P, Hofer A, Thelander L (2006) Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. J Biol Chem 281(12):7834\u20137841","journal-title":"J Biol Chem"},{"issue":"2","key":"5128_CR32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3349\/ymj.2022.0414","volume":"64","author":"MY Seol","year":"2023","unstructured":"Seol MY, Choi SH, Lee IJ, Park HS, Kim HR, Kim SK et al (2023) Selective Inhibition of PI3K isoforms in brain tumors suppresses tumor growth by increasing radiosensitivity. Yonsei Med J 64(2):139","journal-title":"Yonsei Med J"},{"issue":"4","key":"5128_CR33","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/jrr\/rrac018","volume":"63","author":"MY Seol","year":"2022","unstructured":"Seol MY, Choi SH, Yoon HI (2022) Combining radiation with PI3K isoform-selective inhibitor administration increases radiosensitivity and suppresses tumor growth in non-small cell lung cancer. J Radiat Res 63(4):591\u2013601","journal-title":"J Radiat Res"},{"issue":"1","key":"5128_CR34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.4143\/crt.2020.1247","volume":"54","author":"KH Kim","year":"2022","unstructured":"Kim KH, Kim HS, Kim S-s, Shim HS, Yang AJ, Lee JJB et al (2022) Increased radiosensitivity of solid tumors harboring ATM and BRCA1\/2 mutations. Cancer Res Treatment: Official J Korean Cancer Association 54(1):54\u201364","journal-title":"Cancer Res Treatment: Official J Korean Cancer Association"},{"key":"5128_CR35","doi-asserted-by":"publisher","first-page":"650819","DOI":"10.3389\/fcell.2021.650819","volume":"9","author":"Q Wang","year":"2021","unstructured":"Wang Q, Chen Y, Chang H, Hu T, Wang J, Xie Y et al (2021) The role and mechanism of ATM-mediated autophagy in the transition from hyper-radiosensitivity to induced radioresistance in lung cancer under low-dose radiation. Front Cell Dev Biology 9:650819","journal-title":"Front Cell Dev Biology"},{"issue":"2","key":"5128_CR36","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4103\/jcrt.JCRT_1540_20","volume":"19","author":"U Yilmaz","year":"2023","unstructured":"Yilmaz U, Kamer D, Asik A, Kara HG, G\u00fcnd\u00fcz C, Kamer S (2023) The effect of the ATM inhibitor AZD0156 on the radiosensitivity of human breast cancer and lung fibroblast cells. J Cancer Res Ther 19(2):203\u2013207","journal-title":"J Cancer Res Ther"},{"key":"5128_CR37","unstructured":"Clinical Trial of the ATM-Inhibitor (2024) WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors [Internet]"},{"key":"5128_CR38","unstructured":"A Study of RP-3500 in (2024) Combination With Standard Radiation Therapy in People With Solid Tumor Cancer [Internet]"},{"key":"5128_CR39","unstructured":"Trial of XRD (2024) -0394, a kinase inhibitor, in combination with palliative [internet]adiotherapy in advanced Cancer patients [Internet]"},{"issue":"289","key":"5128_CR40","doi-asserted-by":"publisher","first-page":"289ra86","DOI":"10.1126\/scitranslmed.aaa8103","volume":"7","author":"SM Robert","year":"2015","unstructured":"Robert SM, Buckingham SC, Campbell SL, Robel S, Holt KT, Ogunrinu-Babarinde T et al (2015) SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma. Sci Transl Med 7(289):289ra86\u2013ra86","journal-title":"Sci Transl Med"},{"issue":"6","key":"5128_CR41","doi-asserted-by":"publisher","first-page":"N16","DOI":"10.1227\/01.neu.0000473809.76102.ee","volume":"77","author":"RR Zhang","year":"2015","unstructured":"Zhang RR, Pointer KB, Kuo JS (2015) Excitotoxic SLC7A11 expression is a marker of poor glioblastoma survival and a potential therapeutic target. Neurosurgery 77(6):N16\u2013N7","journal-title":"Neurosurgery"},{"issue":"10","key":"5128_CR42","first-page":"3106","volume":"10","author":"W Lin","year":"2020","unstructured":"Lin W, Wang C, Liu G, Bi C, Wang X, Zhou Q et al (2020) SLC7A11\/xCT in cancer: biological functions and therapeutic implications. Am J cancer Res 10(10):3106","journal-title":"Am J cancer Res"},{"key":"5128_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-021-03042-7","volume":"19","author":"L Feng","year":"2021","unstructured":"Feng L, Zhao K, Sun L, Yin X, Zhang J, Liu C et al (2021) SLC7A11 regulated by NRF2 modulates esophageal squamous cell carcinoma radiosensitivity by inhibiting ferroptosis. J Translational Med 19:1\u201316","journal-title":"J Translational Med"},{"key":"5128_CR44","unstructured":"Sulfasalazine in Preventing Acute diarrhea in patients with Cancer who are Undergoing Pelvic Radiation Therapy [Internet]"},{"key":"5128_CR45","unstructured":"Glutamate, Inhibitors in Glioblastoma (GLUGLIO) [Internet]"},{"issue":"10","key":"5128_CR46","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","volume":"273","author":"EP Rogakou","year":"1998","unstructured":"Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM (1998) DNA double-stranded breaks induce histone H2AX phosphorylation on Serine 139. J Biol Chem 273(10):5858\u20135868","journal-title":"J Biol Chem"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05128-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05128-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05128-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T13:10:35Z","timestamp":1757250635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05128-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["5128"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05128-4","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}